UroGen Pharma (URGN) Assets Average (2018 - 2026)

UroGen Pharma (URGN) has 9 years of Assets Average data on file, last reported at $227.1 million in Q1 2026.

• Quarterly Assets Average fell 14.85% year-over-year to $227.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $227.1 million (down 14.85% YoY) and the FY2025 annual result came in at $243.1 million, up 4.77% from the prior year.
• Assets Average rose to $227.1 million in Q1 2026, from $192.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $293.8 million in Q4 2024 to a low of $104.2 million in Q2 2023.
• A 5-year average of $191.5 million and a median of $189.4 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2024 — Assets Average surged 131.58% — and 2025, when it sank 34.4%.
• Tracing URGN's Assets Average over 5 years: stood at $132.0 million in 2022, then soared by 40.84% to $186.0 million in 2023, then soared by 58.0% to $293.8 million in 2024, then slumped by 34.4% to $192.8 million in 2025, then rose by 17.81% to $227.1 million in 2026.
• The last three Assets Average figures came in at $227.1 million (Q1 2026), $192.8 million (Q4 2025), and $196.9 million (Q3 2025), per Business Quant data.